Please login to the form below

Not currently logged in
Email:
Password:

neurodegenerative diseases

This page shows the latest neurodegenerative diseases news and features for those working in and with pharma, biotech and healthcare.

Biogen pays Denali $1bn upfront for Parkinson’s disease programme

Biogen pays Denali $1bn upfront for Parkinson’s disease programme

Denali’s portfolio of small molecule LRRK2 inhibitors and transport vehicle technology platform has potential in a number neurodegenerative diseases, including Parkinson’s disease – the focus of the Biogen deal. ... focused on neurodegenerative

Latest news

More from news
Approximately 3 fully matching, plus 57 partially matching documents found.

Latest Intelligence

  • The search for treatments for Parkinson’s disease The search for treatments for Parkinson’s disease

    and a decade as senior director of neurodegenerative diseases research at Merck Serono where he served as its leader for in vitro pharmacology in neurology, including in multiple sclerosis, Parkinson’s ... and Alzheimer’s diseases.

  • Alzheimer’s: the search for a cure Alzheimer’s: the search for a cure

    big diseases in the field, such as Alzheimer’s, is too limited to make near-term success likely. ... Based on what we felt was the state of the art in terms of understanding the pathogenesis of major diseases, especially neurodegenerative diseases, and

  • A roadmap to the successful treatment of Alzheimer’s disease A roadmap to the successful treatment of Alzheimer’s disease

    Nevertheless, strategies for developing successful therapeutic interventions are shifting. We have developed a five-point roadmap to successful treatments for Alzheimer’s disease and neurodegenerative diseases. ... Hyper-stimulation of microglial cells

  • Brain power: fresh approaches to Alzheimer’s drug discovery Brain power: fresh approaches to Alzheimer’s drug discovery

    The Dementia Consortium provides academic researchers with the funding, industry expertise and project management resources to capitalise on new drug targets for the treatment of the neurodegenerative diseases that cause dementia. ... Diseases include

  • Key considerations for disease- modifying Parkinson’s disease trials Key considerations for disease- modifying Parkinson’s disease trials

    The design of such neuroprotective studies may benefit from the lessons learned in studies in the most common neurodegenerative disease, Alzheimer’s. ... Target early disease stages: It is probably true for all neurodegenerative diseases that symptoms

More from intelligence
Approximately 0 fully matching, plus 13 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 12 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

Switzerland
Switzerland: a life sciences hub
Switzerland has a rich diversity of pharma and biotech companies that sustain activity and help maintain its reputation as a highly innovative country...
Responding to dynamic shifts in value communications
OPEN Health’s Beth Lesher and Annemarie Clegg examine what the convergence of medical communications and market access means for pharmaceutical companies....
Doing what we can and having fun doing it: our fundraising month
Charities are facing a number of challenges just to stay afloat amidst the current COVID-19 pandemic. Fundraisers are being cancelled and public donations are not as abundant as they have...

Infographics